<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511561</url>
  </required_header>
  <id_info>
    <org_study_id>201-201506</org_study_id>
    <nct_id>NCT02511561</nct_id>
  </id_info>
  <brief_title>OTO-201 for the Treatment of Otitis Externa</brief_title>
  <official_title>A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration for Treatment of Otitis Externa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 1-month, multicenter, open-label study in subjects with unilateral otitis externa.&#xD;
      Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear. The study&#xD;
      is designed to characterize safety, procedural factors and clinical effect of OTO-201&#xD;
      administered in subjects with otitis externa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Otoscopic Examination: Tympanic Membrane</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Number of subjects with a tympanic membrane that was rated as &quot;Not able to Visualize&quot; or &quot;Abnormal&quot; at Baseline that was rated as &quot;Normal&quot; at Day 29 (final study day)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Otoscopic Examination: Middle Ear</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Number of subjects with a middle ear that was rated as &quot;Not Able to Visualize&quot; or &quot;Abnormal&quot; at Baseline that had a middle ear rated as &quot;Normal&quot; at Day 29 (final study visit)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of Administration</measure>
    <time_frame>Day1</time_frame>
    <description>Ease of administering OTO-201 to the external ear canal. Number of subjects that investigators rated ease of administration as either &quot;easy&quot; or &quot;very easy&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Adverse Events</measure>
    <time_frame>up to 1 month</time_frame>
    <description>Number of Subjects with and without adverse events during the study from dosing up to 1 month after dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Considered a Clinical Cure at Day 15 (Intent-to-treat Analysis Set)</measure>
    <time_frame>Day 15 (two weeks from dosing)</time_frame>
    <description>Clinical Signs (edema, erythema, otorrhea and otalgia) all had a score of 0 at Day 15. Each sign was graded as follows:&#xD;
None = 0 Mild = 1 Moderate = 2 Severe = 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Considered a Clinical Cure at Day 15 (Per-protocol Analysis Set)</measure>
    <time_frame>Day 15 (2 weeks from dosing)</time_frame>
    <description>Clinical Signs (edema, erythema, otorrhea and otalgia) all had a score of 0 at Day 15. Each sign was graded as follows:&#xD;
None = 0 Mild = 1 Moderate = 2 Severe = 3</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Otitis Externa</condition>
  <arm_group>
    <arm_group_label>0.1 mL OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciprofloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 mL OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciprofloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mL OTO-201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciprofloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTO-201 (ciprofloxacin)</intervention_name>
    <arm_group_label>0.1 mL OTO-201</arm_group_label>
    <arm_group_label>0.2 mL OTO-201</arm_group_label>
    <arm_group_label>0.4 mL OTO-201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria includes, but is not limited to:&#xD;
&#xD;
          -  Subject is a male or female aged 6 months to 80 years, inclusive&#xD;
&#xD;
          -  Subject has a clinical diagnosis of unilateral otitis externa&#xD;
&#xD;
          -  Subject or subject's caregiver is willing to comply with the protocol and attend all&#xD;
             study visits&#xD;
&#xD;
        Exclusion Criteria includes, but is not limited to:&#xD;
&#xD;
          -  Subject has tympanic membrane perforation&#xD;
&#xD;
          -  Subject has a history of known immunodeficiency disease&#xD;
&#xD;
          -  Subject has fungal otitis externa, based on clinical signs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl LeBel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Otonomy, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Email Otonomy Central Contact for Trial Locations</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2020</results_first_posted>
  <last_update_submitted>September 21, 2020</last_update_submitted>
  <last_update_submitted_qc>September 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Otitis externa</keyword>
  <keyword>Swimmer's ear</keyword>
  <keyword>Ear infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Externa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration</description>
        </group>
        <group group_id="P2">
          <title>12 mg OTO-201</title>
          <description>12 mg ciprofloxacin: single administration</description>
        </group>
        <group group_id="P3">
          <title>24 mg OTO-201</title>
          <description>24 mg ciprofloxacin: single administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration</description>
        </group>
        <group group_id="B2">
          <title>12 mg OTO-201</title>
          <description>12 mg ciprofloxacin: single administration</description>
        </group>
        <group group_id="B3">
          <title>24 mg OTO-201</title>
          <description>24 mg ciprofloxacin: single administration</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="21.95"/>
                    <measurement group_id="B2" value="30.0" spread="20.12"/>
                    <measurement group_id="B3" value="43.0" spread="23.74"/>
                    <measurement group_id="B4" value="37.3" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Otoscopic Examination: Tympanic Membrane</title>
        <description>Number of subjects with a tympanic membrane that was rated as &quot;Not able to Visualize&quot; or &quot;Abnormal&quot; at Baseline that was rated as &quot;Normal&quot; at Day 29 (final study day)</description>
        <time_frame>Up to 1 month</time_frame>
        <population>Safety analysis set: All subjects who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O3">
            <title>24 mg OTO-201</title>
            <description>24 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Otoscopic Examination: Tympanic Membrane</title>
          <description>Number of subjects with a tympanic membrane that was rated as &quot;Not able to Visualize&quot; or &quot;Abnormal&quot; at Baseline that was rated as &quot;Normal&quot; at Day 29 (final study day)</description>
          <population>Safety analysis set: All subjects who received study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Otoscopic Examination: Middle Ear</title>
        <description>Number of subjects with a middle ear that was rated as &quot;Not Able to Visualize&quot; or &quot;Abnormal&quot; at Baseline that had a middle ear rated as &quot;Normal&quot; at Day 29 (final study visit)</description>
        <time_frame>Up to 1 month</time_frame>
        <population>Safety analysis set: All subjects that received drug</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O3">
            <title>24 mg OTO-201</title>
            <description>24 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Otoscopic Examination: Middle Ear</title>
          <description>Number of subjects with a middle ear that was rated as &quot;Not Able to Visualize&quot; or &quot;Abnormal&quot; at Baseline that had a middle ear rated as &quot;Normal&quot; at Day 29 (final study visit)</description>
          <population>Safety analysis set: All subjects that received drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of Administration</title>
        <description>Ease of administering OTO-201 to the external ear canal. Number of subjects that investigators rated ease of administration as either &quot;easy&quot; or &quot;very easy&quot;.</description>
        <time_frame>Day1</time_frame>
        <population>Safety analysis set: All subjects who receieved study drug</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O3">
            <title>24 mg OTO-201</title>
            <description>24 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Administration</title>
          <description>Ease of administering OTO-201 to the external ear canal. Number of subjects that investigators rated ease of administration as either &quot;easy&quot; or &quot;very easy&quot;.</description>
          <population>Safety analysis set: All subjects who receieved study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Adverse Events</title>
        <description>Number of Subjects with and without adverse events during the study from dosing up to 1 month after dosing</description>
        <time_frame>up to 1 month</time_frame>
        <population>Safety analysis set: All subjects that received study drug</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 ciprofloxacin: single administration</description>
          </group>
          <group group_id="O3">
            <title>24 mg OTO-201</title>
            <description>24 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Adverse Events</title>
          <description>Number of Subjects with and without adverse events during the study from dosing up to 1 month after dosing</description>
          <population>Safety analysis set: All subjects that received study drug</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of subjects with at least 1 adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of subjects with no adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Considered a Clinical Cure at Day 15 (Intent-to-treat Analysis Set)</title>
        <description>Clinical Signs (edema, erythema, otorrhea and otalgia) all had a score of 0 at Day 15. Each sign was graded as follows:&#xD;
None = 0 Mild = 1 Moderate = 2 Severe = 3</description>
        <time_frame>Day 15 (two weeks from dosing)</time_frame>
        <population>Intent-to-treat analysis set: All subjects who were randomized and were used for assessments of clinical activity</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 ciprofloxacin: single administration</description>
          </group>
          <group group_id="O3">
            <title>24 mg OTO-201</title>
            <description>24 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Considered a Clinical Cure at Day 15 (Intent-to-treat Analysis Set)</title>
          <description>Clinical Signs (edema, erythema, otorrhea and otalgia) all had a score of 0 at Day 15. Each sign was graded as follows:&#xD;
None = 0 Mild = 1 Moderate = 2 Severe = 3</description>
          <population>Intent-to-treat analysis set: All subjects who were randomized and were used for assessments of clinical activity</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Considered a Clinical Cure at Day 15 (Per-protocol Analysis Set)</title>
        <description>Clinical Signs (edema, erythema, otorrhea and otalgia) all had a score of 0 at Day 15. Each sign was graded as follows:&#xD;
None = 0 Mild = 1 Moderate = 2 Severe = 3</description>
        <time_frame>Day 15 (2 weeks from dosing)</time_frame>
        <population>Per-protocol Analysis Set defined as all subjects in the ITT analysis set who received study drug, completed Visit 4 (Day 15), and did not have a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>6 mg OTO-201</title>
            <description>6 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O2">
            <title>12 mg OTO-201</title>
            <description>12 mg ciprofloxacin: single administration</description>
          </group>
          <group group_id="O3">
            <title>24 mg OTO-201</title>
            <description>24 mg ciprofloxacin: single administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Considered a Clinical Cure at Day 15 (Per-protocol Analysis Set)</title>
          <description>Clinical Signs (edema, erythema, otorrhea and otalgia) all had a score of 0 at Day 15. Each sign was graded as follows:&#xD;
None = 0 Mild = 1 Moderate = 2 Severe = 3</description>
          <population>Per-protocol Analysis Set defined as all subjects in the ITT analysis set who received study drug, completed Visit 4 (Day 15), and did not have a major protocol deviation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported during dosing and up to 1 month following dosing.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>6 mg OTO-201</title>
          <description>6 mg ciprofloxacin: single administration</description>
        </group>
        <group group_id="E2">
          <title>12 mg OTO-201</title>
          <description>12 mg ciprofloxacin: single administration</description>
        </group>
        <group group_id="E3">
          <title>24 mg OTO-201</title>
          <description>24 mg ciprofloxacin: single administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication subject to Sponsor consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Otonomy</organization>
      <phone>1-800-826-6411</phone>
      <email>medinfo@otonomy.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

